Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. The supplement and nutritional strategies discussed here are drawn from the published literature and clinical experience but should not replace individualized guidance from a qualified healthcare provider. Ehlers-Danlos syndrome is a complex, multisystem condition, and any supplement regimen should be discussed with a physician or other licensed practitioner experienced in connective tissue disorders. Nothing in this article is intended to diagnose, treat, cure, or prevent any disease.

Supplements and Functional Medicine for Ehlers-Danlos Syndrome:

An Evidence-Informed Guide to Nutritional Support

Guide to Support

By Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine

Osher Fellow - University of Arizona Integrative Medicine Fellowship

Institute of Functional Medicine Scholarship Recipient

directintegrativecare.com

Introduction

Ehlers-Danlos syndrome (EDS) encompasses a group of inherited connective tissue disorders caused by genetic defects in collagen synthesis, processing, or structure. Collagen is the most abundant protein in the human body, responsible for the structural integrity of skin, joints, blood vessels, and virtually every organ system. When collagen is faulty, the consequences ripple outward: joints become hypermobile and prone to subluxation, skin bruises easily and heals slowly, blood vessels may be fragile, and the gastrointestinal tract can lose its structural tone. There are currently thirteen recognized subtypes of EDS, with hypermobile EDS (hEDS) being the most common.

There is no cure for EDS. Conventional management typically centers on physical therapy to stabilize joints, bracing for vulnerable areas, pain management (often with limited success from standard analgesics), and monitoring for cardiovascular complications. For many patients, however, these measures alone are insufficient. This is where functional and integrative medicine offers a complementary framework—one that looks at the whole person, addresses nutritional deficiencies, supports the body’s collagen-producing machinery as fully as possible, and manages the systemic inflammation and fatigue that so often accompany this condition.

A foundational paper by Mantle, Wilkins, and Preedy (2005) proposed a nutritional therapeutic strategy for EDS based on three principles: that nutrition may modulate the expression of genetic disorders, that many EDS symptoms overlap with known nutritional deficiency states, and that synergistic combinations of supplements may promote more normal tissue function. While robust clinical trials specific to EDS remain limited, the biological rationale for targeted nutritional support is strong and continues to grow. This article examines the evidence behind the supplements most commonly discussed in the EDS community, with a commitment to honesty about what we know, what we suspect, and what still needs further study.

The Functional Medicine Approach to EDS

Functional medicine does not aim to replace conventional care for EDS. Rather, it expands the clinical lens. Where conventional medicine may focus primarily on symptom management, functional medicine asks additional questions: Are there modifiable nutritional deficiencies making this patient’s symptoms worse than they need to be? Is systemic inflammation compounding joint pain and fatigue? Is gut dysfunction impairing nutrient absorption? Are there methylation issues that may be contributing to connective tissue instability?

The functional medicine approach to EDS typically includes several integrated strategies. Personalized nutrition addresses both macronutrient adequacy (especially protein, the raw material for collagen) and micronutrient optimization. An anti-inflammatory dietary framework—whether Mediterranean-style, modified low-FODMAP for those with GI involvement, or another individualized approach—forms the dietary foundation. Targeted supplementation addresses specific deficiencies and supports collagen metabolism, energy production, and pain modulation. Gentle, appropriate exercise programs strengthen the muscular scaffolding around hypermobile joints. Attention to gut health is paramount, given that many EDS patients experience gastroparesis, SIBO, or other forms of GI dysmotility that impair nutrient absorption.

This is not a one-size-fits-all protocol. EDS has thirteen subtypes, and even within hEDS the clinical presentation varies enormously from person to person. What works for one patient may not work for another. This reality makes the individualized, systems-based approach of functional medicine particularly well-suited to this population.

Evidence-Informed Supplements for EDS

Before discussing individual supplements, a critical caveat is in order. As the Mayo Clinic’s EDS research group has noted, much of the research on nutritional supplementation for EDS and hypermobility spectrum disorders remains hypothetical in nature. There are very few randomized controlled trials conducted specifically in EDS populations. Much of the evidence is extrapolated from studies in related conditions (osteoarthritis, fibromyalgia, chronic fatigue syndrome, wound healing) or is based on sound biochemical rationale. This does not mean these supplements are useless—it means we must hold our recommendations with appropriate humility and monitor outcomes carefully.

Vitamin C (Ascorbic Acid)

Of all the supplements discussed for EDS, vitamin C has the strongest mechanistic rationale. Ascorbic acid is an essential cofactor for prolyl hydroxylase and lysyl hydroxylase, the enzymes that catalyze the hydroxylation of proline and lysine residues in procollagen—a step absolutely required for stable collagen triple-helix formation. Without adequate vitamin C, collagen cannot fold properly, as dramatically illustrated by scurvy.

Clinical data in EDS is limited but encouraging. In patients with kyphoscoliosis-type EDS (type VI), high-dose vitamin C therapy (1–4 grams per day) has been reported to improve bleeding time, wound healing, and muscle strength over approximately one year of daily use. Mantle et al. proposed a dose of 1,500 mg/day for classic-type EDS based on wound-healing studies showing benefit at 500–3,000 mg daily. Beyond its role in collagen synthesis, vitamin C also functions as a potent antioxidant, scavenging reactive oxygen species that can contribute to tissue damage and inflammation.

Vitamin C is generally well-tolerated. The main side effects at higher doses are GI symptoms (loose stools, nausea), which can be mitigated by using buffered forms or dividing doses throughout the day. For EDS patients with GI dysmotility or malabsorption, liposomal vitamin C or even transdermal delivery may be worth considering to bypass the gut.

Vitamin D3 and Vitamin K2

Vitamin D deficiency is common in the general population and appears to be particularly prevalent among individuals with EDS and hypermobility spectrum disorders. Vitamin D plays essential roles in calcium homeostasis, bone mineralization, immune regulation, and muscle function—all areas of concern in EDS. Given the increased risk of osteoporosis and fractures in many EDS subtypes, maintaining adequate vitamin D status is foundational.

Vitamin K2 (menaquinone) is an important complement to D3 supplementation. K2 activates osteocalcin, the protein responsible for directing calcium into bone rather than into soft tissues and blood vessels. Mantle et al. included vitamin K in their proposed EDS supplement protocol based on its role in bone metabolism and its potential to address the osteoporosis and fracture susceptibility seen in EDS. The combination of D3 and K2 is physiologically synergistic and represents a rational pairing for bone health support in this population.

Magnesium

Magnesium is essential for muscle relaxation, nerve function, energy production, and—importantly for EDS—collagen production. Magnesium deficiency can manifest as muscle cramps, fatigue, migraines, anxiety, and constipation, all of which are common complaints in the EDS population. The Mantle et al. protocol included magnesium as a core component, and research in related conditions provides supportive evidence: a randomized, double-blind study demonstrated that intramuscular magnesium sulfate improved pain, emotional state, and energy levels in chronic fatigue syndrome patients compared to placebo.

Magnesium deficiency appears common in hEDS, potentially due to increased excretion and poor absorption from GI dysfunction. Not all magnesium supplements are created equal. Magnesium glycinate tends to be well-tolerated and calming; magnesium threonate may cross the blood-brain barrier more effectively for cognitive symptoms; magnesium citrate has a mild laxative effect that can actually be helpful for constipation-predominant EDS patients. As an EDS-focused registered dietitian has noted, the evidence specifically linking magnesium supplementation to reduced muscle soreness in EDS is still emerging, and patients should work with their providers to determine the appropriate form and dose for their specific symptom profile.

Coenzyme Q10 (CoQ10)

CoQ10 is a cofactor in mitochondrial ATP production—the fundamental energy currency of every cell in the body. It also functions as a powerful lipid-soluble antioxidant. In the EDS context, CoQ10 has been included in the Mantle et al. nutritional strategy and is frequently discussed in EDS patient communities for its potential to reduce fatigue and oxidative stress.

The published literature supports CoQ10’s role in fatigue management across several conditions that overlap with EDS symptomatology. A meta-analysis demonstrated improvement in fatigue with CoQ10 supplementation among patients with heart failure, multiple sclerosis, fibromyalgia, and healthy individuals. For musculoskeletal weakness and fibromyalgia-type pain, a combination of 250 mg/day carnitine and 100 mg/day CoQ10 has been suggested. CoQ10 has also been associated with reduced mitral valve prolapse symptoms, a finding relevant to the cardiac involvement seen in some EDS subtypes. Mantle et al. specifically noted the overlap between mitral valve prolapse and deficiency of both magnesium and CoQ10.

B Vitamins: B12, Methylfolate, and the Methylation Connection

B12 deficiency is common in EDS and can contribute to fatigue, brain fog, peripheral neuropathy, and mood disturbances. The overlap between EDS and POTS (postural orthostatic tachycardia syndrome) is substantial—some estimates suggest up to 80% of hEDS patients also have POTS—and B1 (thiamine) deficiency has been independently linked to POTS. Methylcobalamin (the active form of B12) is generally preferred over cyanocobalamin, particularly for patients with methylation pathway variants.

The methylation connection deserves special attention. A 2023 paper by Courseault et al. reported a high proportion of MTHFR polymorphisms among EDS patients, leading to the hypothesis that impaired folate metabolism may contribute to connective tissue instability. The MTHFR gene mutation impairs the body’s ability to convert folic acid into its active form (5-methyltetrahydrofolate), and animal studies have suggested that active folate may help regulate MMP2, an enzyme involved in collagen degradation. While this research is still in its early stages and needs replication, it represents a compelling area of investigation. For patients with known MTHFR variants, supplementation with methylfolate (L-5-MTHF) rather than folic acid is a reasonable and low-risk consideration, and monitoring folate levels through regular bloodwork is prudent.

NAD+ and NADH

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular energy metabolism, DNA repair, and mitochondrial function. NAD+ levels naturally decline with age and chronic illness. In the context of EDS, the rationale for NAD+ or NADH supplementation relates primarily to energy production and muscle function. By supporting mitochondrial efficiency, NAD+ may help improve the stamina and muscle performance that EDS patients desperately need to stabilize hypermobile joints.

Research has shown that NADH taken in combination with CoQ10 can improve fatigue in patients with chronic fatigue syndrome, a condition with significant clinical overlap with EDS-related fatigue. A lipid replacement therapy formulation containing both NADH and CoQ10 was shown to significantly reduce fatigue in patients with intractable chronic fatiguing illnesses. While EDS-specific clinical trials are lacking, the biochemical rationale is sound, and precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) are increasingly available and generally well-tolerated.

Glucosamine and Chondroitin

Glucosamine is a natural compound used by the body to produce glycosaminoglycans and proteoglycans—structural components of cartilage, tendons, and ligaments. Chondroitin sulfate works synergistically with glucosamine to support cartilage integrity and may have modest anti-inflammatory effects. The Mantle et al. protocol proposed 1,500 mg/day of glucosamine for joint injury and arthritis symptoms in EDS.

The evidence for glucosamine and chondroitin in osteoarthritis is mixed but generally supportive for symptom relief in a subset of patients. Native collagen type II has also been studied, with some evidence suggesting that 40 mg/day may decrease joint discomfort and increase joint mobility by modulating the inflammatory response. For EDS patients, who experience joint deterioration through a different mechanism than typical osteoarthritis, the benefit is plausible but unproven by EDS-specific trials. These supplements are generally safe and may be worth a therapeutic trial under clinical supervision.

Amino Acids: Glycine, Proline, and Lysine

Glycine, proline, and lysine are the primary amino acid building blocks of collagen. Glycine constitutes approximately one-third of collagen’s amino acid composition. Proline and hydroxyproline (formed from proline via vitamin C-dependent hydroxylation) together make up another significant fraction. Lysine is essential for collagen cross-linking, which gives the molecule its tensile strength.

An important caveat: supplementing with these amino acids does not bypass the underlying genetic defect in EDS. When the body receives amino acids—whether from food, collagen supplements, or individual amino acid supplements—it breaks them down and reassembles them according to its DNA instructions. If the DNA instructions for collagen are faulty, the collagen produced will still be faulty. However, ensuring adequate substrate availability means the body can produce the maximum quantity of whatever quality collagen it is capable of making. For patients with inadequate protein intake or malabsorption (common in EDS with GI involvement), amino acid supplementation may help address a genuine nutritional gap. The goal is not to “fix” the collagen defect but to ensure the body is not working with a shortage of raw materials on top of a structural blueprint problem.

Omega-3 Fatty Acids

Chronic inflammation is a significant driver of pain and fatigue in EDS. Omega-3 fatty acids (EPA and DHA from fish oil or algal sources) are among the best-studied natural anti-inflammatory agents, with well-established effects on prostaglandin metabolism and inflammatory cytokine modulation. For EDS patients who live with daily joint pain, tissue inflammation, and often comorbid conditions like MCAS (mast cell activation syndrome), omega-3 supplementation represents a rational anti-inflammatory strategy.

Dietary sources include fatty fish (salmon, mackerel, sardines), walnuts, flaxseeds, chia seeds, and hemp seeds. For patients who cannot consume adequate omega-3s through diet, high-quality fish oil or algal oil supplements are reasonable. It is worth noting that omega-3s at higher doses can have a mild blood-thinning effect, which warrants caution in vascular EDS subtypes or in patients already on anticoagulant therapy.

Zinc and Copper

Both zinc and copper play roles in collagen metabolism, wound healing, and immune function. Copper is a cofactor for lysyl oxidase, the enzyme responsible for collagen cross-linking—the process that gives connective tissue its structural strength. Zinc supports cell division, tissue repair, and immune regulation. Deficiency of either mineral can impair wound healing and exacerbate connective tissue fragility.

A practical note: zinc and copper must be supplemented in balance. Excessive zinc supplementation can induce copper deficiency, which would be counterproductive for a patient trying to support collagen cross-linking. A typical ratio of 15 mg zinc to 1–2 mg copper is commonly recommended. Testing serum levels of both minerals before supplementing is advisable.

L-Carnitine

Carnitine is essential for transporting long-chain fatty acids into the mitochondria for energy production. It was included in the Mantle et al. protocol and has been recommended at 250 mg/day in combination with CoQ10 for EDS-related myopathy and fatigue. Carnitine deficiency can produce muscle weakness, fatigue, and exercise intolerance—symptoms that closely mirror the daily experience of many EDS patients. While EDS-specific trials are lacking, the biological rationale and safety profile support its consideration as part of a comprehensive energy-support strategy.

MSM (Methyl Sulfonyl Methane) and Silica

MSM provides bioavailable sulfur, which is required for the formation of disulfide bonds in connective tissue proteins. Silica is a trace mineral involved in collagen synthesis and the maintenance of bone, cartilage, and connective tissue integrity. Together, they support the structural framework that EDS compromises. The Mantle et al. protocol included this combination based on their synergistic roles in connective tissue maintenance and joint flexibility. MSM also has modest anti-inflammatory and analgesic properties that may provide additional symptomatic benefit.

Pycnogenol (Pine Bark Extract)

Pycnogenol is a potent antioxidant derived from French maritime pine bark. It was included in the Mantle et al. nutritional strategy for EDS based on its vascular-protective properties, its ability to improve capillary strength (relevant for the easy bruising and fragile blood vessels in EDS), and early evidence of cognitive benefit that may be relevant for EDS-associated brain fog and ADHD-like symptoms. Pycnogenol also appears to bind to collagen and elastin fibers, potentially providing a stabilizing effect on connective tissue.

A Necessary Word About Collagen Supplements

Collagen supplements are enormously popular, and it seems logical that a collagen disorder would respond to collagen supplementation. The reality is more nuanced. When collagen supplements are ingested, they are broken down into individual amino acids during digestion. The body then reassembles those amino acids into new proteins according to its DNA instructions. In EDS, those DNA instructions contain the very mutations that produce faulty collagen in the first place. Supplemental collagen does not bypass the genetic defect.

This does not mean collagen supplements are worthless for EDS patients. They are a convenient source of the amino acids (glycine, proline, hydroxyproline) that serve as collagen precursors. For patients with inadequate protein intake—especially those with GI issues that limit dietary variety—collagen peptides can help fill a genuine nutritional gap. Some patients report subjective improvement in skin quality or joint comfort, and anecdotal reports can sometimes point toward effects that have not yet been captured by formal studies. However, it is important to approach collagen supplementation with realistic expectations: it is a protein source, not a correction of the underlying genetic defect.

The Gut-EDS Connection: Why Absorption Matters

No discussion of supplements for EDS is complete without addressing gut health. Gastrointestinal symptoms are remarkably common in EDS, including gastroparesis, irritable bowel syndrome, functional dyspepsia, SIBO, and structural issues like hiatal hernia and rectal prolapse. These conditions impair nutrient absorption, creating a vicious cycle: the body needs optimal nutrition to support its compromised connective tissue, but the compromised connective tissue in the gut makes optimal nutrition harder to achieve.

A low-FODMAP diet has shown benefit for reducing functional GI symptoms in EDS patients, and fiber supplementation along with probiotic and prebiotic-rich foods can support gut motility and barrier integrity. For patients with significant malabsorption, sublingual, liposomal, or transdermal supplement delivery may be more effective than standard oral formulations. Addressing gut health is not a peripheral concern—it is often the prerequisite for any supplement strategy to work effectively.

Supporting Dysautonomia: Salt, Fluids, and Electrolytes

The high prevalence of POTS and other forms of dysautonomia in EDS adds another layer of nutritional consideration. Adequate salt intake (6–10 grams per day, under medical guidance) and generous fluid intake (1.5–3 liters per day) are cornerstones of dysautonomia management. Electrolyte supplementation—including sodium, potassium, and magnesium—can help maintain blood volume and reduce the dizziness, tachycardia, and exercise intolerance that characterize POTS. This is one area where nutritional intervention has a relatively strong evidence base and can make an immediate, tangible difference in daily functioning.

The Importance of Testing Before Supplementing

A functional medicine principle that I emphasize with my patients is the importance of testing rather than guessing. Common deficiencies in EDS include vitamin D, vitamin B12, magnesium, iron, and folate. Comprehensive nutritional testing—including serum levels of key vitamins and minerals, methylation markers, amino acid profiles, and inflammatory markers—can guide targeted supplementation rather than blanket protocols. This is not only more effective but also safer, as some supplements (iron, copper, fat-soluble vitamins) can accumulate to harmful levels if taken without monitoring.

Putting It Together: A Rational Framework

The supplements discussed in this article are not a replacement for physical therapy, pain management, or the other pillars of EDS care. They are an additional layer of support—one that addresses the nutritional and metabolic terrain in which the genetic defect operates. The goal of supplementation in EDS is not to cure the underlying collagen defect. It is to ensure the body has every possible resource it needs to produce the best collagen it can, to manage the inflammation and oxidative stress that compound the structural problem, and to support the energy production that EDS patients need to maintain the muscular stability their joints require.

A reasonable, evidence-informed starting framework might include: vitamin C for collagen synthesis support; vitamin D3 and K2 for bone health; magnesium for muscle function, nerve support, and energy; CoQ10 for mitochondrial support and fatigue; methylated B vitamins (B12, folate) for energy, cognition, and methylation; omega-3 fatty acids for inflammation; and adequate protein (including collagen precursor amino acids) for substrate availability. Beyond this foundation, additional supplements such as glucosamine, carnitine, NAD+ precursors, MSM/silica, pycnogenol, zinc, and copper may be added based on individual symptom profiles and laboratory findings.

The supplement industry is unregulated, and not all products are created equal. Third-party testing (USP, NSF, ConsumerLab) provides some assurance of quality. Working with a healthcare provider experienced in both EDS and integrative medicine is essential for navigating this landscape safely and effectively.

Conclusion

Living with Ehlers-Danlos syndrome requires a kind of tenacity that those without the condition can scarcely imagine. Every day involves negotiating with a body whose structural foundations are compromised at the molecular level. While we cannot yet change the genetic instructions, we can optimize the nutritional environment in which those instructions operate. Functional medicine offers a framework for doing exactly that—not with false promises, but with a clear-eyed assessment of what the evidence supports, what the biology suggests, and what individual patients report.

The supplements discussed here are tools in a larger toolkit. They work best when combined with appropriate physical therapy, lifestyle modifications, stress management, and—critically—a healthcare team that understands the unique complexities of EDS. If you are living with EDS, I encourage you to work with providers who take a comprehensive, individualized approach and who are willing to partner with you in the ongoing process of finding what works for your body.

References

1. Mantle D, Wilkins RM, Preedy V. A novel therapeutic strategy for Ehlers-Danlos syndrome based on nutritional supplements. Med Hypotheses. 2005;64(2):279-283. doi:10.1016/j.mehy.2004.07.023. PMID: 15607555.

2. DeWane ME, Alshammari ZS, et al. Efficacy of vitamin C supplementation on collagen synthesis and oxidative stress after musculoskeletal injuries: a systematic review. Orthop J Sports Med. 2018;6(10):2325967118804544. PMC6204628.

3. Courseault J, et al. Folate-dependent hypermobility syndrome: a proposed mechanism and diagnosis. Heliyon. 2023;9(4):e15387. PMC10122021.

4. Castori M, et al. Nutritional implications of patients with dysautonomia and hypermobility syndromes. Curr Nutr Rep. 2021;10(4):340-348. PMC8435108.

5. Shashikiran U, Rastogi A, Gupta RP, Sabir M. Ehlers-Danlos syndrome type VI variant presenting with recurrent respiratory infections and responding to high dose vitamin C. Oral Surg Oral Med Oral Pathol. 1982;53:231-236.

6. Voermans NC, Knoop H, van de Kamp N, et al. Fatigue is a frequent and clinically relevant problem in Ehlers-Danlos syndrome. Semin Arthritis Rheum. 2010;40(3):267-274.

7. Nicolson GL, Settineri R, Ellithorpe R. Lipid replacement therapy with a glycophospholipid formulation with NADH and CoQ10 significantly reduces fatigue in intractable chronic fatiguing illnesses and chronic Lyme disease patients. Int J Clin Med. 2012;3(3):163-170.

8. Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet. 1991;337(8744):757-760.

9. Genetics of Ehlers-Danlos Syndrome Treatment & Management. Medscape. Updated 2024. Available at: https://emedicine.medscape.com/article/943567-treatment.

10. Mayo Clinic Connect. Part 3: Supplement safety and resources for EDS/HSD. Ehlers-Danlos Syndrome Blog. Available at: https://connect.mayoclinic.org/blog/ehlers-danlos-syndrome/.

11. Mayo Clinic Connect. Supplements Part 2: Collagen supplements and EDS/HSD. Ehlers-Danlos Syndrome Blog. Available at: https://connect.mayoclinic.org/blog/ehlers-danlos-syndrome/.

12. Gensemer C. Curious about connective tissue? Let’s talk about collagen. Substack. January 2024.

© 2026 Yoon Hang Kim, MD, MPH — Direct Integrative Care

directintegrativecare.com